ArticleDiscover nano2025
Monoamine neurotransmitter functionalized poly(amidoamine) dendrimers for targeting of cabazitaxel to human prostate cancer cells.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer ranks as the second most prevalent solid malignancy in men. Androgen deprivation therapy is a common approach of treating metastatic prostate cancer. However, development of castrate resistance in patients over the course of treatment, non-specific drug distribution and low solubility of drugs are major challenges in the treatment of prostate cancer treatment. In this study, serotonin (ST), a monoamine neurotransmitter, was explored for the site-specific delivery of cabazitaxel (CBZ) to 5HT (5-hydroxytryptamine) receptors overexpressing prostate cancer cells. ST was conjugated to G4 PAMAM dendrimers (DEND) which have well defined, highly branched, nanoscale, multifunctional architecture to carry and enhance the solubility of hydrophobic drugs. This study demonstrates the successful synthesis, characterisation, and CBZ delivery using serotonin-polyethylene glycol-dendrimer complex (ST-PEG-DEND) to DU154 human prostate cancer cells. According to the findings, CBZ@PEG-DEND showed significantly higher time- and dose-dependent cytotoxicities and growth-inhibitory effects to DU145 cells in comparison to pure CBZ. Further, the cellular uptake studies revealed high cellular uptake of targeted and fluorescent conjugate (Rho@ST-PEG-DEND) in comparison to non-targeted fluorescent conjugate (Rho@PEG-DEND), highlighting the role of ST in improved delivery of CBZ to 5HT receptor overexpressed cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.